Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.

Citation data:

Journal of hepatology, ISSN: 1600-0641, Vol: 66, Issue: 6, Page: 1173-1181

Publication Year:
2017
Usage 18
Abstract Views 16
Link-outs 2
Captures 45
Readers 45
Mentions 1
News Mentions 1
Social Media 518
Shares, Likes & Comments 323
Tweets 195
Citations 30
Citation Indexes 30
PMID:
28161470
DOI:
10.1016/j.jhep.2017.01.020
Author(s):
Prenner, Stacey B; VanWagner, Lisa B; Flamm, Steven L; Salem, Riad; Lewandowski, Robert J; Kulik, Laura
Publisher(s):
Elsevier BV
Tags:
Medicine
Most Recent Tweet View All Tweets
Most Recent News Mention
article description
The approval of all-oral direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) has led to the expansion of therapy to include patients with cirrhosis who have hepatocellular carcinoma (HCC). Data on the use of DAAs in HCV+ patients with HCC is limited. The aim of this study was to assess the efficacy of all-oral-DAA regimens in HCV+ cirrhotic patients who have or had HCC compared to those without HCC.